首页 > 最新文献

Recenti progressi in medicina最新文献

英文 中文
[Patients with heart failure experience fewer hospitalizations and reduced mortality when treated with mineralocorticoid receptor antagonists.]
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43921
Alice Serafini, Linda Speer, Peter K Kurotschka
{"title":"[Patients with heart failure experience fewer hospitalizations and reduced mortality when treated with mineralocorticoid receptor antagonists.]","authors":"Alice Serafini, Linda Speer, Peter K Kurotschka","doi":"10.1701/4392.43921","DOIUrl":"https://doi.org/10.1701/4392.43921","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"606-607"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Luciano Gattinoni: medico, scienziato, innovatore, maestro. 卢西亚诺-加蒂诺尼:医生、科学家、创新者、教师。
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43938
Giuseppe R Gristina
{"title":"Luciano Gattinoni: medico, scienziato, innovatore, maestro.","authors":"Giuseppe R Gristina","doi":"10.1701/4392.43938","DOIUrl":"https://doi.org/10.1701/4392.43938","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"643-644"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Può la scienza post-normale applicarsi all’oncologia radioterapica? Le incertezze della scienza nelle conoscenze disciplinari. 后常态科学能否应用于放射肿瘤学?学科知识中科学的不确定性。
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43926
Angelo Di Naro, Maurizio Portaluri, Roberta Muni, Micaela Motta, Santa Bambace, Alessandra Castelluccia, Francesco Tramacere, Michele Sala, Simonetta Cesa, Bruna De Marchi

Post-Normal Science (PNS) was introduced about 30 years ago to address the changing relation between science and governance when science is called upon to provide inputs to policy-related issued. Originally concerned mainly with environmental risks, in the last decades the PNS approach has been applied to a growing and diversified number of issues. It is considered particularly appropriate in situations characterized by: uncertain facts, a plurality of potentially conflicting values, high stakes, and urgent decisions. The objective of this paper is to present a survey that will test the opinions of practitioners and stakeholders on the usefulness of the PNS approach for addressing three emerging issues within the field of radiation oncology: the high and growing number of expected patients, the number of sessions per radiotherapy cycle, and treatment in old age. Respondents will also be asked to indicate which of the typical PNS intervention tools - such as extended and inclusive dialogue, the use of hybrid tools, adaptability and flexibility, and transparency in decision-making -are most suitable, and to what extent. Professionals and stakeholders from one radiotherapy center in northern Italy and two centers in southern Italy will be interviewed.

{"title":"Può la scienza post-normale applicarsi all’oncologia radioterapica? Le incertezze della scienza nelle conoscenze disciplinari.","authors":"Angelo Di Naro, Maurizio Portaluri, Roberta Muni, Micaela Motta, Santa Bambace, Alessandra Castelluccia, Francesco Tramacere, Michele Sala, Simonetta Cesa, Bruna De Marchi","doi":"10.1701/4392.43926","DOIUrl":"https://doi.org/10.1701/4392.43926","url":null,"abstract":"<p><p>Post-Normal Science (PNS) was introduced about 30 years ago to address the changing relation between science and governance when science is called upon to provide inputs to policy-related issued. Originally concerned mainly with environmental risks, in the last decades the PNS approach has been applied to a growing and diversified number of issues. It is considered particularly appropriate in situations characterized by: uncertain facts, a plurality of potentially conflicting values, high stakes, and urgent decisions. The objective of this paper is to present a survey that will test the opinions of practitioners and stakeholders on the usefulness of the PNS approach for addressing three emerging issues within the field of radiation oncology: the high and growing number of expected patients, the number of sessions per radiotherapy cycle, and treatment in old age. Respondents will also be asked to indicate which of the typical PNS intervention tools - such as extended and inclusive dialogue, the use of hybrid tools, adaptability and flexibility, and transparency in decision-making -are most suitable, and to what extent. Professionals and stakeholders from one radiotherapy center in northern Italy and two centers in southern Italy will be interviewed.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"616-617"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effective treatment for Helicobacter pylori infection in adults: the 2024 American College of Gastroenterology guideline recommendations.] [有效治疗成人幽门螺旋杆菌感染:2024 年美国胃肠病学院指南建议]。
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43919
Viviana Forte, Henry Barry, Peter K Kurotschka
{"title":"[Effective treatment for Helicobacter pylori infection in adults: the 2024 American College of Gastroenterology guideline recommendations.]","authors":"Viviana Forte, Henry Barry, Peter K Kurotschka","doi":"10.1701/4392.43919","DOIUrl":"10.1701/4392.43919","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"601-603"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultra limes. 超级酸橙
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43935
Angelica Salvadori, Enrico d'Alessandro, Federico Stroppiana

In the period between March 2021 and December 2023, our Casa della Salute in Borgaretto (Torino) organized a clinic dedicated to vaccination against Covid-19 in its local and with its staff (medical, nursing and administrative). To try to inform the majority of the population about this activity, we used the social networks of the Casa della Salute (Facebook and website), the social networks of the Municipality of Beinasco and some of the local newspapers. The list of eligible subjects was shared with the ASL TO 3 and the invitation to vaccination was made via SMS from a dedicated platform, indicating the day and time of the appointment. All the actors involved participated in multiple organizational meetings to share the logistical aspect and the management of any critical events. 10.167 vaccines were administered, the vaccination sessions lasted 6 hours each, the vaccination days were 112, with an average of 90 patients per session. This vaccination campaign, albeit in an emergency context, was made possible by the good organization of all the Casa della Salute staff, integrated with the ASL TO 3 and the Municipality of Beinasco. None of the three entities, alone, would probably have been able to obtain the same result: the ability to integrate and the will to cooperate were fundamental.

{"title":"Ultra limes.","authors":"Angelica Salvadori, Enrico d'Alessandro, Federico Stroppiana","doi":"10.1701/4392.43935","DOIUrl":"https://doi.org/10.1701/4392.43935","url":null,"abstract":"<p><p>In the period between March 2021 and December 2023, our Casa della Salute in Borgaretto (Torino) organized a clinic dedicated to vaccination against Covid-19 in its local and with its staff (medical, nursing and administrative). To try to inform the majority of the population about this activity, we used the social networks of the Casa della Salute (Facebook and website), the social networks of the Municipality of Beinasco and some of the local newspapers. The list of eligible subjects was shared with the ASL TO 3 and the invitation to vaccination was made via SMS from a dedicated platform, indicating the day and time of the appointment. All the actors involved participated in multiple organizational meetings to share the logistical aspect and the management of any critical events. 10.167 vaccines were administered, the vaccination sessions lasted 6 hours each, the vaccination days were 112, with an average of 90 patients per session. This vaccination campaign, albeit in an emergency context, was made possible by the good organization of all the Casa della Salute staff, integrated with the ASL TO 3 and the Municipality of Beinasco. None of the three entities, alone, would probably have been able to obtain the same result: the ability to integrate and the will to cooperate were fundamental.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"636-637"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilizzo dei Real World Data per definire la popolazione target di nuove indicazioni terapeutiche: l’esempio delle terapie CAR-T. 利用真实世界数据确定新治疗适应症的目标人群:以 CAR-T 疗法为例。
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43936
Michela Servadio, Valeria Belleudi, Marco Finocchietti, Ilaria Cozzi, Marina Davoli, Antonio Addis

CAR-T therapies are a form of innovative and personalised immunotherapy in the field of onco-haematology. Diffuse large B-cell lymphoma (DLBCL) is a very aggressive form of non-Hodgkin's lymphoma (NHL) for which CAR-T therapies are approved as 3rd-line and more recently (from 11/11/2023), as 2nd-line for patients who relapse within 12 months after 1st-line chemo-immunotherapy. This study was conducted to estimate the eligible DLBCL population for CAR-T therapies in 2024 in Lazio region. Starting with a cohort of DLBCL patients from a previous work, a series of proportions were first obtained applying the eligibility criteria for CAR-T, and then applied to the annual incident cases of NHL in Lazio region. From 1,353 NHL cases, 392 (29%) were considered DLBCL of which 82% (322) received first line chemo-immunotherapy. They were then divided into two groups: with relapse ≤12 months (Group 1) and with relapse >12 months (Group 2). Fifty percent of Group 1 (46 cases) and part of those not eligible to ASCT (35%=16 cases) constitute the eligible population for CAR-T therapy as 2nd-line. From the 29 cases of Group 2, were calculated the proportions of CAR-T eligible patients among those not eligible for ASCT (35%=5 cases) and those who did not respond to salvage chemotherapy (65%=4 cases) and with post-transplant relapse (39%=3 cases). A total of 74 DLBCL patients were found to be eligible for CAR-T therapies. This study demonstrates that the use of Real World Data is a valuable tool in defining the target population for new therapeutic indications.

CAR-T 疗法是肿瘤血液学领域一种创新的个性化免疫疗法。弥漫大 B 细胞淋巴瘤(DLBCL)是一种侵袭性很强的非霍奇金淋巴瘤(NHL),CAR-T疗法已被批准作为三线疗法,最近(自 2023 年 11 月 11 日起)又被批准作为二线疗法,用于治疗一线化疗免疫疗法后 12 个月内复发的患者。本研究旨在估算拉齐奥大区 2024 年符合 CAR-T 疗法治疗条件的 DLBCL 患者人数。从之前一项研究的 DLBCL 患者队列开始,首先应用 CAR-T 的资格标准得出一系列比例,然后应用于拉齐奥地区每年的 NHL 发病病例。在1353例NHL病例中,392例(29%)被认为是DLBCL,其中82%(322例)接受了一线化疗免疫疗法。随后,他们被分为两组:复发时间≤12个月(第1组)和复发时间>12个月(第2组)。第1组中的50%(46例)和部分不符合ASCT条件的患者(35%=16例)构成了CAR-T疗法二线治疗的合格人群。从第2组的29例患者中,计算出符合CAR-T条件的患者在不符合ASCT条件者(35%=5例)、对挽救性化疗无反应者(65%=4例)和移植后复发者(39%=3例)中所占的比例。共有74名DLBCL患者符合CAR-T疗法的治疗条件。这项研究表明,使用真实世界数据是确定新治疗适应症目标人群的重要工具。
{"title":"Utilizzo dei Real World Data per definire la popolazione target di nuove indicazioni terapeutiche: l’esempio delle terapie CAR-T.","authors":"Michela Servadio, Valeria Belleudi, Marco Finocchietti, Ilaria Cozzi, Marina Davoli, Antonio Addis","doi":"10.1701/4392.43936","DOIUrl":"https://doi.org/10.1701/4392.43936","url":null,"abstract":"<p><p>CAR-T therapies are a form of innovative and personalised immunotherapy in the field of onco-haematology. Diffuse large B-cell lymphoma (DLBCL) is a very aggressive form of non-Hodgkin's lymphoma (NHL) for which CAR-T therapies are approved as 3rd-line and more recently (from 11/11/2023), as 2nd-line for patients who relapse within 12 months after 1st-line chemo-immunotherapy. This study was conducted to estimate the eligible DLBCL population for CAR-T therapies in 2024 in Lazio region. Starting with a cohort of DLBCL patients from a previous work, a series of proportions were first obtained applying the eligibility criteria for CAR-T, and then applied to the annual incident cases of NHL in Lazio region. From 1,353 NHL cases, 392 (29%) were considered DLBCL of which 82% (322) received first line chemo-immunotherapy. They were then divided into two groups: with relapse ≤12 months (Group 1) and with relapse >12 months (Group 2). Fifty percent of Group 1 (46 cases) and part of those not eligible to ASCT (35%=16 cases) constitute the eligible population for CAR-T therapy as 2nd-line. From the 29 cases of Group 2, were calculated the proportions of CAR-T eligible patients among those not eligible for ASCT (35%=5 cases) and those who did not respond to salvage chemotherapy (65%=4 cases) and with post-transplant relapse (39%=3 cases). A total of 74 DLBCL patients were found to be eligible for CAR-T therapies. This study demonstrates that the use of Real World Data is a valuable tool in defining the target population for new therapeutic indications.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"638-639"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
La figura professionale del farmacista ospedaliero oltre i confini nazionali.
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43923
Agnese Bosio, Chiara Carcieri, Sixberth Bugeraha, Silvia Scalpello, Giovanna Fazzina, Maria Carmen Azzolina, Gianluca Miglio, Annalisa Gasco

The objective of this study is to identify the essential hard and soft skills that healthcare professionals must develop when working in a low- and middle-income country (LMIC), where the socio-economic and cultural context differs significantly from that of Italy. The analysis was conducted following a period of observation conducted by a hospital pharmacy resident at a rural hospital in southern Tanzania. In order to ascertain the role and requisite competencies for hospital pharmacists (HPs) in LMICs, an investigation was conducted based on the 24 competencies identified by EAHP. The skills identified relate to patient care and clinical pharmacy, drug skills, management skills and professional skills. HPs in LMICs play a role in the final follow-up of hospital prescriptions, requiring in-depth knowledge of drugs. Communication, therapeutic education and follow-up are very important in a setting where primary care is lacking. Moreover, given the limited availability of resources, management and professional skills are crucial. The analysis has shown how, in different working contexts, health professionals are stimulated to develop and implement mainly specific skills, the sharing of which, through field experiences, can lead to a bilateral improvement of the services and health care offered.

{"title":"La figura professionale del farmacista ospedaliero oltre i confini nazionali.","authors":"Agnese Bosio, Chiara Carcieri, Sixberth Bugeraha, Silvia Scalpello, Giovanna Fazzina, Maria Carmen Azzolina, Gianluca Miglio, Annalisa Gasco","doi":"10.1701/4392.43923","DOIUrl":"https://doi.org/10.1701/4392.43923","url":null,"abstract":"<p><p>The objective of this study is to identify the essential hard and soft skills that healthcare professionals must develop when working in a low- and middle-income country (LMIC), where the socio-economic and cultural context differs significantly from that of Italy. The analysis was conducted following a period of observation conducted by a hospital pharmacy resident at a rural hospital in southern Tanzania. In order to ascertain the role and requisite competencies for hospital pharmacists (HPs) in LMICs, an investigation was conducted based on the 24 competencies identified by EAHP. The skills identified relate to patient care and clinical pharmacy, drug skills, management skills and professional skills. HPs in LMICs play a role in the final follow-up of hospital prescriptions, requiring in-depth knowledge of drugs. Communication, therapeutic education and follow-up are very important in a setting where primary care is lacking. Moreover, given the limited availability of resources, management and professional skills are crucial. The analysis has shown how, in different working contexts, health professionals are stimulated to develop and implement mainly specific skills, the sharing of which, through field experiences, can lead to a bilateral improvement of the services and health care offered.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"610-611"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
La fluidità dei confini: il diritto alla salute ha un genere? 界限的流动性:健康权有性别之分吗?
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43927
Asia Di Pietro, Daniela Di Grazia, Francesco Chiara, Maura Caudana, Francesco M A Shelton Agar, Marina Zanatta, Sarah Allegra, Giuliana Abbadessa, Silvia De Francia

The aim of the work was to create a survey related to health questions to be distributed to associations active for trans* people's rights. 165 answers were obtained: among these, 45.6% are from trans* people and 31.3% from cisgender women. Different gender identifications are reported by trans* people who answered to the survey. Finally, among all the answers obtained, 71.3% have never received information about a gender-personalized medicine and 79.4% have never received informations about different therapeutic choices. From the comments collected in the survey's open field, three macro-themes emerged: disinformation, pathologization, and lack of economic resources. It is then necessary to break all prejudices to respect the right to health of trans* people, who are still invisible within health systems today.

{"title":"La fluidità dei confini: il diritto alla salute ha un genere?","authors":"Asia Di Pietro, Daniela Di Grazia, Francesco Chiara, Maura Caudana, Francesco M A Shelton Agar, Marina Zanatta, Sarah Allegra, Giuliana Abbadessa, Silvia De Francia","doi":"10.1701/4392.43927","DOIUrl":"https://doi.org/10.1701/4392.43927","url":null,"abstract":"<p><p>The aim of the work was to create a survey related to health questions to be distributed to associations active for trans* people's rights. 165 answers were obtained: among these, 45.6% are from trans* people and 31.3% from cisgender women. Different gender identifications are reported by trans* people who answered to the survey. Finally, among all the answers obtained, 71.3% have never received information about a gender-personalized medicine and 79.4% have never received informations about different therapeutic choices. From the comments collected in the survey's open field, three macro-themes emerged: disinformation, pathologization, and lack of economic resources. It is then necessary to break all prejudices to respect the right to health of trans* people, who are still invisible within health systems today.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"618-619"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Sacituzumab govitecan in the treatment of triple-negative metastatic breast cancer.]
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43916
Marta Perachino, Matteo Lambertini

The clinical management of triple-negative breast cancer has been very difficult for a long time, being classical chemotherapy the only possible therapeutic approach given the absence of specific targets. However, the therapeutic armamentarium has recently been expanded thanks to the introduction of new molecules, in particular immunotherapy and antibody-drug conjugates (ADCs), which have made it possible to significantly improve the prognosis of this patient population both in the early and advanced settings. Since 2022, the ADC sacituzumab govitecan has been approved by the Italian Medicines Agency (Aifa) for the treatment of advanced/metastatic triple-negative breast cancer pretreated with at least two lines of systemic therapy, of which at least one for metastatic disease. In the collection of case reports, we delved into the available data on the efficacy profile and impact on quality of life of sacituzumab govitecan in several special populations of patients with triple-negative metastatic breast cancer.

长期以来,三阴性乳腺癌的临床治疗一直非常困难,由于缺乏特异性靶点,传统化疗是唯一可能的治疗方法。然而,由于新分子的引入,特别是免疫疗法和抗体药物结合体(ADC)的引入,治疗手段最近得到了扩展,这使得这一患者群体在早期和晚期的预后都得到了显著改善。自 2022 年起,ADCsacituzumab govitecan 已获得意大利药品管理局(Aifa)批准,用于治疗至少接受过两线全身治疗(其中至少一线用于转移性疾病)的晚期/转移性三阴性乳腺癌。在收集的病例报告中,我们深入研究了现有数据,了解了三阴性转移性乳腺癌患者中几个特殊人群使用萨希珠单抗戈维替康的疗效概况及其对生活质量的影响。
{"title":"[Sacituzumab govitecan in the treatment of triple-negative metastatic breast cancer.]","authors":"Marta Perachino, Matteo Lambertini","doi":"10.1701/4392.43916","DOIUrl":"https://doi.org/10.1701/4392.43916","url":null,"abstract":"<p><p>The clinical management of triple-negative breast cancer has been very difficult for a long time, being classical chemotherapy the only possible therapeutic approach given the absence of specific targets. However, the therapeutic armamentarium has recently been expanded thanks to the introduction of new molecules, in particular immunotherapy and antibody-drug conjugates (ADCs), which have made it possible to significantly improve the prognosis of this patient population both in the early and advanced settings. Since 2022, the ADC sacituzumab govitecan has been approved by the Italian Medicines Agency (Aifa) for the treatment of advanced/metastatic triple-negative breast cancer pretreated with at least two lines of systemic therapy, of which at least one for metastatic disease. In the collection of case reports, we delved into the available data on the efficacy profile and impact on quality of life of sacituzumab govitecan in several special populations of patients with triple-negative metastatic breast cancer.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"588-592"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ambulatorio infermieristico Casa di Comunità di Ponte di Legno. 护理门诊部 Casa di Comunità di Ponte di Legno。
Q3 Medicine Pub Date : 2024-12-01 DOI: 10.1701/4392.43931
Patrizia Laffranchini, Giulia Zanini, Elena Muffolini, Fausta Omodei, Giuseppina Barcellini

The Asst Valcamonica faces significant challenges in providing continuity of care services due to a shortage of medical personnel, exacerbated by its location in a mountainous area and the seasonal variability of tourism. To address these needs, a temporary nursing-run clinic was developed, aimed at providing healthcare to tourists, particularly during August 2023. The Family and Community Nurse (IFeC) plays a crucial role in primary care, working in synergy with remote medical consultations to ensure an integrated care model; provide first-level healthcare during peak tourist periods. And experiment with a network organizational model with nursing management and teleconsultation between nurse and physician. The project was implemented from 7 to 25 August 2023, with an organizational network that included a nursing clinic managed by an IFeC at the Community House of Ponte di Legno, and the collaboration with the Integrated Medical Center of the Regional Emergency Agency for remote medical consultations. The service operated from Monday to Friday, from 10:00 to 17:00. During the activation period, there were 186 visits recorded. Of these, 87 were requests for information and 99 were requests for services. 86% of nursing management was deemed sufficient. Only 3% required a teleconsultation with the CMI physician, while 10% were directed to the Emergency Room. The nursing clinic model could be replicated in other Community Houses with high tourist influx. The implementation of a system based on nursing triage and teleconsultation could enhance assistance in both Tourist Continuity of Care and Primary Care.

由于地处山区,加之旅游业的季节性变化,瓦尔卡蒙尼卡急救中心在提供连续性护理服务方面面临着巨大挑战,而医务人员的短缺又加剧了这一挑战。为了满足这些需求,开发了一个由护士管理的临时诊所,旨在为游客提供医疗保健服务,尤其是在 2023 年 8 月期间。家庭和社区护士(IFeC)在初级保健中发挥着至关重要的作用,与远程医疗咨询协同工作,确保综合护理模式;在游客高峰期提供一级保健服务。并尝试采用护理管理和护士与医生之间远程会诊的网络组织模式。该项目于 2023 年 8 月 7 日至 25 日实施,其组织网络包括在 Ponte di Legno 社区之家设立一个由 IFeC 管理的护理诊所,并与地区急救机构的综合医疗中心合作进行远程医疗会诊。服务时间为周一至周五的 10:00 至 17:00。在启动期间,共记录了 186 次访问。其中 87 次为信息请求,99 次为服务请求。86% 的护理管理被认为是充分的。只有 3% 的患者需要与 CMI 医生进行远程会诊,10% 的患者被引导至急诊室。护理门诊模式可在其他游客较多的社区之家推广。实施基于护理分诊和远程会诊的系统可以加强对游客持续护理和初级护理的帮助。
{"title":"Ambulatorio infermieristico Casa di Comunità di Ponte di Legno.","authors":"Patrizia Laffranchini, Giulia Zanini, Elena Muffolini, Fausta Omodei, Giuseppina Barcellini","doi":"10.1701/4392.43931","DOIUrl":"https://doi.org/10.1701/4392.43931","url":null,"abstract":"<p><p>The Asst Valcamonica faces significant challenges in providing continuity of care services due to a shortage of medical personnel, exacerbated by its location in a mountainous area and the seasonal variability of tourism. To address these needs, a temporary nursing-run clinic was developed, aimed at providing healthcare to tourists, particularly during August 2023. The Family and Community Nurse (IFeC) plays a crucial role in primary care, working in synergy with remote medical consultations to ensure an integrated care model; provide first-level healthcare during peak tourist periods. And experiment with a network organizational model with nursing management and teleconsultation between nurse and physician. The project was implemented from 7 to 25 August 2023, with an organizational network that included a nursing clinic managed by an IFeC at the Community House of Ponte di Legno, and the collaboration with the Integrated Medical Center of the Regional Emergency Agency for remote medical consultations. The service operated from Monday to Friday, from 10:00 to 17:00. During the activation period, there were 186 visits recorded. Of these, 87 were requests for information and 99 were requests for services. 86% of nursing management was deemed sufficient. Only 3% required a teleconsultation with the CMI physician, while 10% were directed to the Emergency Room. The nursing clinic model could be replicated in other Community Houses with high tourist influx. The implementation of a system based on nursing triage and teleconsultation could enhance assistance in both Tourist Continuity of Care and Primary Care.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"626-627"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recenti progressi in medicina
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1